Cargando…

Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer

Detalles Bibliográficos
Autores principales:	Elsea, David, Fan, Lin, Mihai, Adela, Moustaid, Fadoua El, Simmons, Daniel, Monberg, Matthew, Muston, Dominic
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596628/ https://www.ncbi.nlm.nih.gov/pubmed/36107308 http://dx.doi.org/10.1007/s41669-022-00372-0

Ejemplares similares

Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
por: Elsea, David, et al.
Publicado: (2022)

Olaparib and bevacizumab in front-line maintenance of ovarian cancer: an over reliance in unpowered subgroup analysis of the PAOLA-1 trial?
por: Paulino, Eduardo, et al.
Publicado: (2020)

Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial
por: Pujade-Lauraine, Eric, et al.
Publicado: (2023)

Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma
por: Christinat, Yann, et al.
Publicado: (2023)

Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials
por: Fan, Lin, et al.
Publicado: (2022)

The cost-effectiveness analysis of maintenance olaparib plus Bevacizumab in patients with advanced ovarian cancer: based on the final survival results from PAOLA-1 trial
por: Zhu, Youwen, et al.
Publicado: (2023)

Retrospective efficacy analysis of olaparib combined with bevacizumab in the treatment of advanced colorectal cancer
por: Jiang, Yi-Ling, et al.
Publicado: (2023)

Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial
por: Fujiwara, Keiichi, et al.
Publicado: (2021)

Treatment of polypoidal choroidal vasculopathy with intravitreal bevacizumab monotherapy
por: Tan, Colin S H, et al.
Publicado: (2013)

A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)
por: Lee, Yong Jae, et al.
Publicado: (2021)

A Retrospective Study Comparing Olaparib and Bevacizumab as a Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: Impact on Recurrence-Free Survival in Japanese and Asian Populations
por: Nakanishi, Kazuho, et al.
Publicado: (2023)

Bevacizumab in the treatment of ovarian cancer
por: Eskander, Ramez N, et al.
Publicado: (2011)

Intravitreal bevacizumab monotherapy for treatment-naive polypoidal choroidal vasculopathy
por: Chhablani, Jay Kumar, et al.
Publicado: (2014)

Intravitreal bevacizumab monotherapy for treatment-naïve polypoidal choroidal vasculopathy
por: Chhablani, Jay Kumar, et al.
Publicado: (2013)

Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA)
por: Gao, Qinglei, et al.
Publicado: (2022)

Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer
por: Lorusso, Domenica, et al.
Publicado: (2022)

Subthreshold micropulse laser adjuvant to bevacizumab versus bevacizumab monotherapy in treating diabetic macular edema: one- year- follow-up
por: El Matri, Leila, et al.
Publicado: (2021)

Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer
por: Stein, Alexander, et al.
Publicado: (2015)

Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer
por: Wilson, Andrew J., et al.
Publicado: (2021)

Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer
por: Hettle, Robert, et al.
Publicado: (2021)

Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells
por: Mani, Chinnadurai, et al.
Publicado: (2019)

The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review
por: Poku, Edith, et al.
Publicado: (2014)

TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
por: Liu, Cheng-Jiang, et al.
Publicado: (2021)

Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours
por: Dean, E, et al.
Publicado: (2012)

A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)
por: Cloughesy, Timothy F, et al.
Publicado: (2020)

Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date
por: Montemorano, Lauren, et al.
Publicado: (2019)

Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status Phase II LIGHT study primary analysis
por: Cadoo, Karen, et al.
Publicado: (2022)

Predictive value of angiogenic proteins in patients with metastatic melanoma treated with bevacizumab monotherapy
por: Schuster, Cornelia, et al.
Publicado: (2018)

Critical appraisal of bevacizumab in the treatment of ovarian cancer
por: Yoshida, Hiroyuki, et al.
Publicado: (2015)

Current status of bevacizumab in advanced ovarian cancer
por: Tomao, Federica, et al.
Publicado: (2013)

Bevacizumab as adjunct to chemotherapy for chemoresistant ovarian cancer
por: Hamilton, Gerhard
Publicado: (2020)

Safety Analysis of Bevacizumab in Ovarian Cancer Patients
por: Wang, Yingwen, et al.
Publicado: (2023)

Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4
por: Kim, Yoo-Na, et al.
Publicado: (2023)

Combination of bevacizumab and photodynamic therapy vs. bevacizumab monotherapy for the treatment of wet age-related macular degeneration: A meta-analysis of randomized controlled trials
por: Wei, Qingquan, et al.
Publicado: (2018)

Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models
por: Oliva, P, et al.
Publicado: (2012)

VEGF-C serum level is associated with response to bevacizumab maintenance therapy in primary ovarian cancer patients
por: Ding, Yi, et al.
Publicado: (2022)

Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib
por: Botrus, Gehan, et al.
Publicado: (2022)

Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
por: Bellier, Charlotte, et al.
Publicado: (2023)

Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
por: Ledermann, Jonathan A., et al.
Publicado: (2019)

Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer
por: Ogita, Shin, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_j4pjndts2dl77jtov6ajljceq1